Melbourne, Aug 15, 2011 (ABN Newswire) - Global regenerative medicine company, Mesoblast Limited (
ASX:MSB) (PINK:MBLTY), today announced that its heart failure clinical trial has been chosen by the American Heart Association to be featured at its 2011 annual conference in Orlando, Florida, in the "Clinical Science: Special Reports" session on November 14. More than 17,000 international cardiovascular specialists are expected to attend the conference.
Results from the randomized, placebo-controlled Phase 2 trial of Mesoblast's allogeneic, or off-the-shelf, adult stem cell product, Revascor(TM), in patients with moderate-severe congestive heart failure will be presented by Dr Emerson C. Perin, Director of Research in Cardiovascular Medicine and Medical Director, Stem Cell Center, Texas Heart Institute, Houston.
The Phase 2 trial compared safety and efficacy outcomes in 45 patients who received a single injection of Revascor(TM) on top of standard-of-care with 15 patients who received standard-of-care alone. An important objective of the trial was to determine whether treatment with Revascor(TM) could positively impact on hard endpoints expected to be met in a subsequent Phase 3 trial for licensure approval by the United States Food and Drug Administration (FDA).
Mesoblast Chief Executive, Professor Silviu Itescu, said: "We are very pleased that the American Heart Association has selected our congestive heart failure trial of Revascor(TM) for presentation in the Special Reports session at their annual conference.
"Mesoblast is developing Revascor(TM) as an innovative therapy for a broad-based cardiovascular franchise, including the treatment of acute myocardial infarction and chronic refractory angina in addition to congestive heart failure.
"This forum provides an excellent opportunity for a wide audience of cardiovascular experts to be exposed to Mesoblast's proprietary cutting-edge technology and our robust clinical results," he added.
ASX:MSB) (PINK:MBLTY), today announced that its heart failure clinical trial has been chosen by the American Heart Association to be featured at its 2011 annual conference in Orlando, Florida, in the "Clinical Science: Special Reports" session on November 14. More than 17,000 international cardiovascular specialists are expected to attend the conference.Results from the randomized, placebo-controlled Phase 2 trial of Mesoblast's allogeneic, or off-the-shelf, adult stem cell product, Revascor(TM), in patients with moderate-severe congestive heart failure will be presented by Dr Emerson C. Perin, Director of Research in Cardiovascular Medicine and Medical Director, Stem Cell Center, Texas Heart Institute, Houston.
The Phase 2 trial compared safety and efficacy outcomes in 45 patients who received a single injection of Revascor(TM) on top of standard-of-care with 15 patients who received standard-of-care alone. An important objective of the trial was to determine whether treatment with Revascor(TM) could positively impact on hard endpoints expected to be met in a subsequent Phase 3 trial for licensure approval by the United States Food and Drug Administration (FDA).
Mesoblast Chief Executive, Professor Silviu Itescu, said: "We are very pleased that the American Heart Association has selected our congestive heart failure trial of Revascor(TM) for presentation in the Special Reports session at their annual conference.
"Mesoblast is developing Revascor(TM) as an innovative therapy for a broad-based cardiovascular franchise, including the treatment of acute myocardial infarction and chronic refractory angina in addition to congestive heart failure.
"This forum provides an excellent opportunity for a wide audience of cardiovascular experts to be exposed to Mesoblast's proprietary cutting-edge technology and our robust clinical results," he added.
| Tweet |
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.
Mesoblast's commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.
The company's lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.
Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.
|
||
|
 |
Related Companies |
>>>       Mesoblast Limited |
| |
Related Industry Topics: |
Biotech | Financial General | Health & Pharm General | |
| |
This Page Viewed: (Last 7 Days: 140) (Last 30 Days: 490) (Since Published: 12170) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
Companies in the News
Mobile Video TV
|
||
|
||
){kind=link}